Hong Kong Pharmaceuticals & Healthcare Report Q1 2014 - New Market Study Published
Despite its small market size, Hong Kong's drug procurement is intensely regulated by the Hospital Authority (HA). As a result, companies that are able to supply to the HA stand to benefit. We highlight that Hong Kong is lagging behind other Asian countries such as Singapore, South Korea, China and Japan in terms of support for pharmaceutical research and development, which could limit investment into the sector.
View full press release